Lonza Expands Peptide API Manufacturing at Visp Facility
2024-10-22
Lonza expands peptide API manufacturing capacity at its Visp site, adding commercial-scale SPPS infrastructure for long-term peptide supply contracts.
Lonza Group has announced the expansion of its peptide manufacturing facility in Visp, Switzerland. The move is a strategic initiative that enhances Lonza's role as a dominant player in the global peptide API segment, capable of meeting the increasing need for personalized medicine and biologics.
The expansion adds commercial-scale SPPS infrastructure and integrated services to serve long-term peptide supply contracts. This investment positions Lonza to capture growing demand from pharmaceutical companies developing GLP-1 receptor agonists and other peptide-based therapeutics.
Read Full Source Article